4//SEC Filing
JANNEY DANIEL 4
Accession 0001711279-23-000023
CIK 0001711279other
Filed
Apr 20, 8:00 PM ET
Accepted
Apr 21, 4:10 PM ET
Size
5.9 KB
Accession
0001711279-23-000023
Insider Transaction Report
Form 4
JANNEY DANIEL
Director
Transactions
- Sale
Common Stock
2023-04-19$90.32/sh−7,900$713,493→ 224,462 total(indirect: Directly beneficially owned by Alta Bioequities, L.P.)
Footnotes (3)
- [F1]The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 12, 2022 and will terminate on September 11, 2023 and contemplates sales of 25,000 shares with a limit price of $90.00 per share.
- [F2]The transaction was executed in multiple trades ranging from $90.0000 to $90.3650. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F3]Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Documents
Issuer
Krystal Biotech, Inc.
CIK 0001711279
Entity typeother
Related Parties
1- filerCIK 0001198325
Filing Metadata
- Form type
- 4
- Filed
- Apr 20, 8:00 PM ET
- Accepted
- Apr 21, 4:10 PM ET
- Size
- 5.9 KB